Uses of modified rna encoding retinaldehyde dehydrogenase
AssigneePresident and Fellows of Harvard College
InventorsUlrich H. Von Andrian, Bruno Raposo
Life of this patent
Estimating the term…
Abstract
Some aspects of this disclosure provide modified mRNA (modRNA) encoding retinaldehyde dehydrogenase (RALDH) enzyme, in addition to methods of synthesis, administration, use, and treatment. In some embodiments, the modRNA may be used in a vaccine to treat infections (e.g., mucosal infections) and/or cancers (e.g., mucosal cancers).
Claims160
A messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a retinaldehyde dehydrogenase (RALDH) protein, wherein at least one uridine is pseudouridine, and at least one cytosine is 5-methylcytosine.
A vaccine comprising:
- (a) at least one antigen;
- and
- (b) at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a retinaldehyde dehydrogenase (RALDH) protein, wherein at least one uridine is pseudouridine and at least one cytosine is 5-methylcytosine.
A tolerogenic vaccine comprising
- (a) at least one antigen;
- (b) an immunomodulatory agent;
- and
- (c) at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a retinaldehyde dehydrogenase (RALDH) protein, wherein at least one uridine is pseudouridine and at least one cytosine is 5-methylcytosine.
A cancer vaccine, comprising
- (a) at least one mucosal tumor antigen or immunogenic polypeptide fragment thereof;
- (b) at least one adjuvant;
- and
- (c) at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) encoding a retinaldehyde dehydrogenase (RALDH) protein, wherein at least one uridine is pseudouridine and at least one cytosine is 5-methylcytosine.
Dependencies are inferred from the claim text.